Meropenem Generis Phar

Meropenem, the active ingredient in Meropenem Generis Phar, is a carbapenem antibiotic presented as a sterile powder for intravenous use. It treats severe bacterial infections such as intra‑abdominal, urinary, respiratory, bloodstream, and skin infections in hospitalized patients. GNH USA supplies Meropenem Generis Phar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections across several organ systems.

Complicated intra‑abdominal infections: provides rapid bacterial eradication in the peritoneal cavity. Complicated urinary tract infections: eliminates resistant uropathogens causing pyelonephritis. Nosocomial pneumonia: treats hospital‑acquired lung infections, including ventilator‑associated pneumonia. Septicemia: achieves systemic bacterial clearance in bloodstream infections. Skin and soft tissue infections: resolves deep tissue infections caused by Gram‑negative and Gram‑positive organisms.

Adverse reactions may occur with any antimicrobial therapy. Monitoring for side effects is recommended during treatment.

Common Side Effects: - Nausea or vomiting - Diarrhea, including mild Clostridioides difficile colitis - Headache - Infusion‑site phlebitis or pain - Transient elevation of liver enzymes - Mild rash or pruritus

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment or CNS disease - Severe allergic reactions (anaphylaxis, Stevens‑Johnson syndrome) - Clostridioides difficile‑associated colitis requiring intensive care - Acute renal failure or worsening renal function - Neutropenia or agranulocytosis - Hepatotoxicity with jaundice or hepatic failure

Prior to initiating therapy, clinicians should assess patient‑specific factors and monitor for potential complications. - Renal function: adjust dose in patients with impaired clearance to avoid toxicity. - Hepatic function: monitor liver enzymes in patients with pre‑existing liver disease. - Neurological status: use caution in patients with a history of seizures or CNS disorders. - Concomitant antibiotics: evaluate for additive neurotoxicity when combined with other β‑lactams. - Pregnancy and lactation: weigh benefits against potential risks; data are limited. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Valproic acid: reduces plasma concentrations of valproate, increasing seizure risk. - Other β‑lactam antibiotics: additive risk of neurotoxicity and seizures. - Cytotoxic chemotherapy agents: may potentiate neurotoxic effects.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor electrolytes and renal function. - Aminoglycosides: watch for synergistic nephrotoxicity. - Warfarin: observe INR for possible anticoagulation changes.